In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Complete Resection of Contrast Enhancing Tumor Volume is Associated with Improved Survival in Recurrent Glioblastoma – Results from the DIRECTOR Trial

    Final Number:
    136

    Authors:
    Bogdana Suchorska MD; Michael Weller MD; Ghazaleh Tabatabai MD; Christian Senft MD, PhD; Peter Hau; Michael Sabel MD; Ulrich Herrlinger MD; Ralf Ketter MD; Uwe Schlegel MD; Christine Marosi MD; Guido Reifenberger MD, PhD; Wolfgang Wick; Joerg-Christian Tonn MD; Hans-Georg Wirsching MD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2015 Annual Meeting

    Introduction: The role of reoperation for recurrent glioblastoma is still unclear due to lack of prospective studies. Here, we report on the association of clinical outcome with surgery for recurrent glioblastoma including volumetric extent of resection in the well characterized patient cohort of the DIRECTOR trial. This prospective randomized multicenter study evaluated the effect of two different dose-intensified temozolomide regimens at first recurrence of glioblastoma.

    Methods: We analyzed prospectively collected clinical, molecular and imaging data from the DIRECTOR cohort (N = 105). Imaging data were available from 87 patients. Volumetric analysis was performed based on gadolinium (Gd) enhancement on MRI and correlated with progression-free survival (PFS) and overall survival (OS). Proportional hazard models were applied to obtain prognostic factors.

    Results: 71 of 105 patients received surgery at recurrence. Prognostic factors such as age (p = 0.358), MGMT promoter methylation (p = 0.965), IDH-1 mutation (p = 0.724), Karnofsky performance score (p = 0.880), or steroid intake before randomization (p = 0.950 were balanced between patients with and without reoperation. Mean tumor volumes at study entry were smaller in patients who had received surgery than in patients without (3.0 cm3 [range 0-37] versus 6.8 cm3[range 1-23], p < 0.001). The outcomes in patients with/without surgery at recurrence were similar for PFS (2.0 months vs. 1.9 months, p = 0.1974) and OS (9.2 months vs 9.4 months , p = 0.9538). Among patients who underwent reoperation, post-surgery imaging was available in 59 cases. In these patients, complete resection of Gd-enhancing tumor (N = 39) versus residual detection of Gd enhancement (N = 20) was associated with significantly improved OS (11.5 months [95% CI 9.3-15.1] vs. 6.7 months [95% CI 5.2-9.5], p = 0.006).

    Conclusions: Surgery at first recurrence of glioblastoma seems to improve outcome if complete resection of Gd-enhancing tumor volume is feasible.

    Patient Care: To better select patients with recurrent glioblastoma who will benefit from reoperation

    Learning Objectives: By the conclusion of this session,participants should be able to: 1) describe the effect of tumor resection of recurrent glioblastoma on overall survival 2) discuss prognostic factors in recurrent glioblastoma 3) report on the effect of dose intense rechallenge with temozolomide in recurrent glioblastoma

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy